Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study
Clinical & Experimental Ophthalmology · 2024-07 · 52 (5) · 507-515
DOI: 10.1111/ceo.14368 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 23.02.2024. Verfasst von Samantha Sze-Yee Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Ophthalmology and Visual Science (incorporating the Lions Eye Institute), University of Western Australia, Perth, Western Australia, Austr…. Hauptthemen laut MEDLINE: Atropine, Disease Progression, Ophthalmic Solutions, Mydriatics. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ophthalmic Research Institute of Australia, Raine Medical Research Foundation, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
A rebound in myopia progression following cessation of atropine eyedrops has been reported, yet there is limited data on the effects of stopping 0.01% atropine compared to placebo control. This study tested the hypothesis that there is minimal rebound myopia progression after cessation of 0.01% atropine eyedrops, compared to a placebo.
Methods
Children with myopia ( n = 153) were randomised to receive 0.01% atropine eyedrops or a placebo (2:1 ratio) daily at bedtime during the 2‐year treatment phase of the study. In the third year (wash‐out phase), all participants ceased eyedrop instillation. Participants underwent an eye examination every 6 months, including measurements of spherical equivalent (SphE) after cycloplegia and axial length (AL). Changes in the SphE and AL during the wash‐out phase and throughout the 3 years of the study (treatment + wash‐out phase) were compared between the treatment and control groups.
Results
During the 1‐year wash‐out phase, SphE and AL progressed by −0.41D (95% CI = −0.33 to −0.22) and +0.20 mm (95% CI = −0.46 to −0.36) in the treatment group compared to −0.28D (95% CI = 0.11 to 0.16) and +0.13 mm (95% CI = 0.18 to 0.21) in the control group. Progression in the treatment group was significantly faster than in the control group ( p = 0.016 for SphE and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Ophthalmology and Visual Science (incorporating the Lions Eye Institute), University of Western Australia, Perth, Western Australia, Australia.
- Centre for Eye Research Ireland, Environmental, Sustainability and Health Institute, Technological University Dublin, Dublin, Ireland.
- Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
- Perth Children's Hospital, Perth, Western Australia, Australia.
- School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia.
ORCID-Profile: Samantha Sze-Yee Lee, Vinay Kumar Nilagiri, Gareth Lingham, Magdalena Blaszkowska, Paul G Sanfilippo, Maria Franchina, Antony Clark, David A Mackey
Förderung
- Ophthalmic Research Institute of Australia
- Raine Medical Research Foundation
- Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia
- Telethon Kids Institute
- University of Western Australia
- Telethon-Perth Children's Hospital Research Fund
- Healy Medical Research Foundation
- National Health and Medical Research Council
Zitieren
APA
Lee, S. S., Nilagiri, V. K., Lingham, G., Blaszkowska, M., Sanfilippo, P. G., Franchina, M., Clark, A., & Mackey, D. A. (2024). Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study. Clinical & Experimental Ophthalmology, 52(5), 507-515. https://doi.org/10.1111/ceo.14368
Vancouver
Lee SS, Nilagiri VK, Lingham G, Blaszkowska M, Sanfilippo PG, Franchina M, et al. Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study. Clinical & Experimental Ophthalmology. 2024;52(5):507-515. doi:10.1111/ceo.14368
BibTeX
@article{Lee2024,
author = {Lee, Samantha Sze-Yee and Nilagiri, Vinay Kumar and Lingham, Gareth and Blaszkowska, Magdalena and Sanfilippo, Paul G and Franchina, Maria and Clark, Antony and Mackey, David A},
title = {Myopia progression following 0.01% atropine cessation in Australian children: Findings from the Western Australia – Atropine for the Treatment of Myopia ( WA‐ATOM ) study},
journal = {Clinical & Experimental Ophthalmology},
year = {2024},
volume = {52},
number = {5},
pages = {507--515},
doi = {10.1111/ceo.14368}
}
EUVIMED